ADX-2191 for Vitreoretinal Lymphoma

This trial tests a new treatment called ADX-2191 for primary vitreoretinal lymphoma, a rare eye cancer. Researchers aim to assess the safety and effectiveness of ADX-2191 when injected into the eye. Participants will join one of two groups: one receiving regular injections and another with a different dosing schedule. Individuals diagnosed with this specific eye cancer and with lymphomatous cells in their eye fluid are suitable candidates for the trial. As a Phase 3 trial, this study serves as the final step before FDA approval, providing participants an opportunity to contribute to the potential availability of a new treatment.

The trial requires that you stop using systemic methotrexate at least one week before starting treatment. For other medications, the protocol does not specify, so it's best to discuss with the trial team.

Research has shown that ADX-2191, a treatment for primary vitreoretinal lymphoma, has not raised any major safety concerns. Studies found that the FDA identified no safety or manufacturing issues with ADX-2191, indicating that patients generally tolerate the treatment well. Additionally, the FDA granted orphan drug status to ADX-2191 for other conditions, which involved a detailed review of safety data. Although the FDA did not approve it for primary vitreoretinal lymphoma due to insufficient evidence of effectiveness, safety was not a factor in the denial. Thus, the treatment appears safe for use.¹²³⁴⁵

Unlike the standard treatments for vitreoretinal lymphoma, which typically involve radiation and chemotherapy, ADX-2191 offers a unique approach by being directly injected into the eye. This method allows the drug to target the lymphoma cells more precisely, potentially leading to fewer side effects compared to systemic treatments. Researchers are excited about ADX-2191 because it has the potential to provide more effective and localized treatment, improving outcomes for patients with this challenging condition.

Research shows that ADX-2191, a new methotrexate injection tested in this trial, may help treat primary vitreoretinal lymphoma, a rare eye cancer. In earlier studies, ADX-2191 demonstrated promising results, such as reducing the risk of retinal detachment over six months compared to past data. This trial includes two treatment arms: one where participants receive an Induction/Consolidation/Maintenance (ICM) regimen of ADX-2191 injections, and another where participants receive monthly ADX-2191 injections. Europe has recognized the treatment for its potential to address this rare condition. Currently, no FDA-approved treatments exist for primary vitreoretinal lymphoma, but ADX-2191 could become the first if ongoing research continues to yield positive outcomes.²³⁶⁷⁸